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Abstract
Background: Anorexia nervosa (AN) and Obsessive Compulsive Disorder (OCD) are among the most incapacitating
and costly of mental disorders. Cognitive Behaviour Therapy (CBT), medication, and combination regimens, to
which in AN personalised guidance on weight control is added, are moderately successful, leaving room for more
effective treatment algorithms. An underlying deficit which the two disorders share is cognitive inflexibility, a trait
that is likely to impede treatment engagement and reduce patients’ ability to benefit from treatment. Cognitive
remediation therapy (CRT) is an easy-to-use intervention aimed at reducing cognitive inflexibility and thereby
enhancing treatment outcome, which we aim to test in a controled study.
Methods: In a randomized-controlled multicenter clinical trial 64 adult patients with AN and 64 with OCD are
randomized to 10 bi-weekly sessions with either CRT or a control condition, after which Treatment As Usual (TAU) is
started. All patients are evaluated during single-blind assessments at baseline, post-CRT/control intervention, and
after 6 months. Indices of treatment effect are disorder-specific symptom severity, quality of life, and cost-effectivity.
Also, moderators and mediators of treatment effects will be studied.
Discussion: To our knowledge, this is the first randomized controlled trial using an control condition evaluating the
efficacy and effectiveness of CRT as a treatment enhancer preceding TAU for AN, and the first study to investigate
CRT in OCD, moreover taking cost-effectiveness of CRT in AN and OCD into account.
Trial registration: The Netherlands Trial Register NTR3865. Registered 20 february 2013.
Keywords: Cognitive remediation, Anorexia nervosa, Obsessive compulsive disorder, Psychological treatment
Background
Anorexia nervosa (AN) is a severely debilitating eating
disorder characterized by self-starvation with both nega-
tive physiological and psychological effects. Individuals
with AN assign extreme over-importance to body weight
and shape, making it central to their self-evaluation, and
develop an abnormal body-image perception.
Obsessive Compulsive Disorder (OCD) is character-
ized by recurrent obsessions and compulsions that cause
marked distress and interfere with daily functioning [1].
More specifically, obsessions are defined as intrusive, re-
petitive thoughts, images, or impulses, and compulsions
as purposeful, repetitive overt and covert behaviours per-
formed to relieve obsessional distress.
Several studies have investigated potential relation-
ships between AN and OCD based on the phenotypic
features the two disorders have in common, such as re-
petitive and ritualistic behaviours, excessive habit forma-
tion, and cognitive rigidity [2]. Interestingly, several
studies demonstrated rates of AN among OCD patients,
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and reversely rates of OC symptoms among AN patients
to be higher than expected by chance, with OCD fre-
quencies ranging between 9,5 and 62 % in patients with
AN, and anorexia nervosa-rates up to 11–13 % in clin-
ical OCD populations [3–8].
Further, there is accumulating evidence that patients
suffering from AN and OCD share specific inefficiencies
in executive functioning affecting attention processes,
set-shifting/cognitive flexibility, processing speed, visuo-
spatial abilities, inhibition of ongoing cognitive and
motor responses, and working memory [9–14]. Specific
inefficiencies in executive functioning are central to the
development and maintenance of obsessions and com-
pulsions as seen in both AN and OCD [15, 16].
It is suggested that particularly cognitive inflexibil-
ity maintains and exacerbates compulsive behaviours
in both AN and OCD [17, 18]. Some degree of cog-
nitive inflexibility is also found in first-degree rela-
tives [19–21], i.e. a difficulty to shift to a different
thought or action according to changes in a situation
[22]. These inefficiencies are associated with the
neurobiological (fronto-striatal) abnormalities associ-
ated with repetitive behaviours in AN and OCD [23].
Thus, patients seem to rely heavily on low-energy but
highly automated and stereotyped repetitive behav-
iours, at the cost of higher-energy but more diverse
goal-directed and flexible behaviours [24].
Furthermore, individuals with AN show a cognitive
style in which there is a bias towards local or detailed-
focus processing of information over the natural ten-
dency to integrate information into a for the person rele-
vant context [25]. In line with this, individuals with
OCD show inefficiencies in global information process-
ing and a detailed and less systematic organizational
strategy [26, 27].
Finally and consistent with previous research, adults
suffering from AN and OCD show specific visuospatial
memory inefficiencies [26, 28, 29].
Arguably, these inefficiencies may prevent patients
from successfully engaging in therapy and may decrease
both treatment motivation and the efficacy of psycho-
logical interventions.
Symptom-based treatment for OCD and AN
Treatment schemes for AN and OCD are generally
aimed at symptom reduction. Standard treatment of
adult AN consists of a combination of renourishment
and psychotherapy. Clinical effects of either supportive
clinical management, CBT, focal psychodynamic therapy,
family therapy, or interpersonal psychotherapy are com-
parable [30–32]. Only 46% of patients recover fully, one
third achieves partial improvement (showing residual
symptoms), and 20% remains chronically ill [33]. One
significant challenge in the treatment of individuals with
AN concerns the ambivalence towards treatment. Intrin-
sic motivation to enable behavioural changes is often
low [34].
According to European guidelines, the treatment of
OCD should typically encompass CBT usually in com-
bination with pharmacotherapy, specifically selective
serotonin reuptake inhibitors (SSRIs) [35, 36]. Despite
reasonable effect sizes (Cohen’s d around 1.0) [37–39],
only 22% of OCD patients having received CBT recovers
completely [37]. In a recent meta-analysis, Sharma et al.
[40] found that 47% of all patients with OCD (treated or
untreated) do not achieve complete remission. Thus,
rates of incomplete recovery and treatment resistance
remain relatively high [41, 42].
Moreover, in OCD non-compliance as to pharmaco-
therapy is common, as is dropout from CBT (with attri-
tion rates between 13 and 27%) [43–47]. Dropout rates
from treatment in outpatients with AN are even higher
(ranging from 48 to 100%) [48].
Clearly, optimizing therapy results for AN and OCD
remains a major challenge for both researchers and ther-
apists. In the past decades various attempts have been
made to develop supportive interventions to enhance
adherence and effectivety, with an increasing interest in
approaches that target underlying inefficiencies instead
of the main symptoms of the disorder itself.
The relatively low success rates of guideline-directed
therapies for AN and OCD, together with the inefficien-
cies in executive functioning that sufferers seem to
share, have prompted the notion that patients might
benefit from a training module that addresses and reme-
diates these underlying inefficiencies.
Cognitive remediation therapy
Recently, a cognitive intervention, i.e. Cognitive Remedi-
ation Therapy (CRT) has been adapted for eating disor-
ders including AN, which specifically focuses on
improving the cognitive inflexibility and organizational
inefficiencies described above [49, 50]. CRT was origin-
ally developed for the treatment of patients with trau-
matic brain injuries but has also been applied in patients
with attention deficit hyperactivity disorder (ADHD),
learning disabilities [51] and schizophrenia. Although in
schizophrenia results have been mixed, symptom reduc-
tion as well as improvement of cognitive and social func-
tioning, and normalisation of neural activity have been
described [52, 53]. CRT aims at improving cognitive
flexibility, central coherence, global information process-
ing, reducing perfectionism and improving the aware-
ness of dysfunctional thinking styles.
In CRT for AN, patients carry out cognitive excercies
and are encouraged to reflect on their typical, maladap-
tive daily-life strategies, and to consider and practice
helpful alternatives, for instance by adopting more global
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‘bigger-picture’ thinking strategies and more goal-
directed behaviours. A recent meta-analysis on all avail-
able case reports has shown that CRT improves the cog-
nitive performance of patients with severe AN and that
the intervention is feasible and well tolerated [54]. Three
recent randomized controlled trials (RCTs) similarly
found evidence of its effectiveness in AN [55–57].
Dingemans et al. [57] demonstrated CRT preceding
TAU to be more effective than TAU alone: the interven-
tion boosted improvement in terms of ED-specific
health-related quality of life (QoL) indices (Cohen’s d:
1.36), while ED-related psychopathology was lower at
follow-up than it was following TAU alone (Cohen’s d:
0.99). Patients with relatively poor baseline set-shifting
abilities showed greater long-term improvements in
quality of life in the CRT group when compared to the
control group. The authors accordingly concluded that
CRT shows promise as a treatment enhancer. Although
CRT has not directly been studied in OCD, two RCTs in
OCD have tested similar approaches in OCD. Starting
from the hypothesis of strengthening executive functions
to foster later symptom reduction, Buhlman et al. [58]
investigated a cognitive retraining program aimed at re-
ducing organizational inefficiencies. Both OCD and con-
trol participants who underwent training improved more
in organization and memory than participants who did
not receive organizational training. The authors con-
cluded that in OCD organizational capacities can be
augmented. They however did not study the effects of
this training on OCD symptoms. Second, in a promising
RCT on the effects of a cognitive training program to
improve organizational skills in 15 OCD patients com-
pared to 15 controls, Park et al. [59] found that visual
memory functions and obsessive-compulsive symptoms
improved more in the treated group than in the control
group.
Methods/design
The study design is reported in line with the SPIRIT
2013 Statement (Standard protocol Items: Recom-
mendations for Interventional Trials) [60]. The Med-
ical Ethics Committee of the University Medical
Centre Utrecht has approved the study (METc no.
NL43751.041.13 v.03).
Study aims
The primary goal of the current ongoing study is to
examine the treatment enhancing effect of CRT on treat-
ment as usual (TAU, guideline directed therapy) in AN
and OCD. The secondary aim is to investigate the cost-
effectiveness and budget impact of CRT. The third aim
is to study which patient characteristics determine posi-
tive benefits from CRT-based treatment enhancement.
More specifically, we study several moderators and me-
diators of response (Table 1).
Our research questions read as follows:
1) To what extend does CRT prior to TAU for AN and
CBT for OCD enhance treatment outcome?
2) To what extend is addition of CRT to TAU more
cost-effective?
3) What are moderators of treatment-enhancing effect
of CRT in AN and OCD?
4) What are mediators of treatment-enhancing effect of
CRT in AN and OCD?
Design
Figure 1 provides an overview of the study design. In a
randomized controlled multicentre trial, we compare
two treatment arms, i.e. CRT and, in the control condi-
tion, Specialized Attention Therapy (SAT), both deliv-
ered in 10 twice weekly sessions as an adjunct to TAU
for AN and OCD. Patients are assessed at baseline (T0),
directly following CRT or SAT completion and prior to
symptom based TAU (T1), at 6 months after T0; (T2),
and at 12 months after T0 (T3). All patients receive both
oral and written information and are enrolled after they
have provided written informed consent.
Participants
Patients aged between 18 and 60 years are recruited
from four Dutch tertiary clinics specialized in the treat-
ment of anxiety and eating disorders. Patients diagnosed
with AN (both restrictive and binge/purge subtype) are
recruited from Altrecht Eating Disorders Rintveld, Zeist,
and Rivierduinen Eating Disorders Ursula, Leiden, and
patients with OCD from Altrecht Academic Anxiety
Centre, Utrecht, and Overwaal Centre for Anxiety Disor-
ders, Nijmegen. Most of the patients referred to these
centres suffer from moderate to severe AN or OCD.
Eligible are patients whose AN (or eating disorder not
otherwise specified, clinically referred to as AN) or OCD
diagnosis is consistent with the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition text revision
(DSM-IV-TR ).
The criteria for exclusion are: severe neurological illness
(including a history of seizures, stroke, or Parkinson’s dis-
ease), severe comorbid psychiatric disorder (clinical sig-
nificant major depressive disorder, current acute phase of
bipolar disorder, current psychosis, substance depend-
ence/abuse), intellectual impairment, defined as an IQ
< 80, estimated with the Dutch Adult Reading Test
(DART) [61], which is a Dutch version of the
National Adult Reading Test (NART) [62], and inabil-
ity to adequately speak or read Dutch. Current use of
antidepressants and antipsychotics is allowed provided
that dosages are kept constant during the experimental
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part of the study. Since benzodiazepines can dampen the
effect of cognitive treatments [63], their use is restricted
to a daily maximum dose (up to 20 mg for temazepam or
an equivalent dose) taken as a sleep medication. On re-
quest, patients can withdraw their participation at any
time.
Inclusion and exclusion criteria are verified with the
aid of the structured clinical interview for DSM-IV-TR
axis I disorders (SCID-I [64]), while for OCD patients to
be enrolled, a Yale-Brown Obsessive-Compulsive
Severity Scale score ≥16 is required [65, 66]. In all pa-
tients comorbidity with either OCD or AN is allowed.
Procedure and randomization
All participating centres adhere to standardized intake
and screening procedures. The therapist performing the
screening informs patients meeting the inclusion criteria
about the study and ask their permission to have a re-
search assistant contact them by phone or in person to
invite them to participate in the trial, after which
Table 1 Measures to assess screening, outcome, mediator and moderator variables
Function Measure Instrument T0 T1 T2 T3
Screening Diagnostic status SCID X
Primary outcome AN severity EDE-Q X X X X
OCD severity Y-BOCS X X X X
Secondary outcome OCD severity OCI-R X X X X
Quality of life EQ-5D X X X X
ED-Qol c X X X X
OCD-Qol b X X X X
Daily functioning WSAS X X X X
Healthcare utilization and production loss TIC-P X X X X
Depression BDI-II X X X X
General anxiety BAI X X X X
Mediators Cognitive flexibility Stroop X X X X
D-Flex X X X X
TMT X X X X
Response inhibition SSRT X X X X
Central coherence GEFT X X X X
Intolerance of uncertainty IUS X X X X
Perfectionism CPQ X X X X
Self-efficacy PEPPI-5 X X X X
Behaviour inhibition/activation BISBAS X X X X
Therapeutic engagement SRS a X
Moderators Demographics, e.g. sex, age, education level Interview X
Diagnostic status SCID-I X
Obsessive compulsive personality disorder SCID-II-OCPD X
Autism AQ X
ADHD CAARS-S:SV b X
Cognitive flexibility ID/EDS b X
Planning ability BADS-Zoo-map X
EDQ Eating Disorder Examination Questionnaire, Y-BOCS Yale-Brown Obsessive Compulsive Scale, OCI-R Obsessive-Compulsive Inventory-revised, EQ-5D EuroQuol,
ED-Qol Eating Disorder Quality of life questionnaire, OCD-Qol Obsessive-Compulsive Disorder Quality of life questionnaire, WSAS Work and Social Adjustment Scale,
TIC-P Trimbos/iMTA Questionnaire for Cost Associated with Psychiatric Illness, BDI-II Beck Depression Inventory, second revision, BAI Beck Anxiety Inventory, Stroop
Stroop task, D-FLEX Detail and Flexibility Questionnaire, TMT Trail making test, SSRT Stop Signal Reaction Task, GEFT Group embedded figures Test, IUS Intolerance
of uncertainty scale, CPQ Clinical perfectionism questionnaire, PEPPI-5 Perceived Efficacy in Patient-Physician Interactions, BISBAS Behavioural Inhibition and Behav-
ioural Activation Scales, SRS Session Rating Scale, SCID-I Structured Clinical Interview for DSM-IV-TR Axis I disorders, SCID-II Structured Clinical Interview for DSM-IV-
TR Axis II disorders, section obsessive-compulsive personality disorder, AQ Autism-spectrum Quotient, CAARS-S:SV Connors’ Adult ADHD Rating Scales, self report,
short version, ID/EDS Intra dimensional-/extra dimensional shift paradigm, BADS-Zoo map Behavioural Assessment of the Dysexecutive Syndrome, Zoo Map
a after each CRT/SAT session
b OCD Only
c AN Only
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interested patients are sent or given a brochure describ-
ing the study. At least 1 week later baseline assessments
are carried out after written informed consent is ob-
tained. After baseline assessments patients not meeting
inclusion-criteria are excluded. Patients satisfying all the
study criteria are subsequently randomized to one of the
two study conditions. An independent research coordin-
ator who is not involved in the therapies or assessments
uses SPSS/IBM [67] to create a randomization sequence
stratified by treatment centre with a 1:1 allocation using
random block sizes of 4. Given the nature of the study
design, all patients and therapists are aware of the treat-
ment condition (CRT or SAT). Patients are informed
that both treatment arms are being investigated as to
their potential to enhance subsequent TAU. The thera-
pists delivering CRT or SAT are instructed not to reveal
the treatment condition to the research assistant con-
ducting the assessments; unintended violation of asses-
sor blindness is recorded.
Measures
Table 1 provides a list of screening, outcome, mediator
and moderator measures. Assessments to monitor treat-
ment progress are performed at baseline (T0), after 2
months (post-CRT or SAT and prior to TAU) (T1), and
6 months after the baseline TAU (T2), and after 12
months (T3) This measurement will encompass the
same instruments as used at T2. All patients are exten-
sively re-evaluated using (validated or recommended)
indices of treatment effect and costs, quality of life, and
cognitive and behavioural flexibility, which will entail
self-reports, structured clinical interviews, and paper-
and-pen as well as computerized neuropsychological
tests. All screening and outcome data are collected in a
central database using SPSS/IBM [67].
Screening measures
The Structured Clinical Interview for DSM-IV-TR Axis I
disorders (SCID-I) [64] and the Structured Clinical
Interview for DSM-IV-TR Axis II disorders (SCID-II)
[68] are used to assess diagnostic status. The SCID-I
[64] and SCID-II [68] are semi-structured interviews.
Both interviews are organized by the DSM-IV classifica-
tions. The inter-rater reliability and validity of SCID-I
and SCID-II interviews are fair to excellent depending
the diagnosis [69] For the present study we used the full
SCID-I and only the section on obsessive-compulsive
personality disorder from the SCID-II.
Outcome measures
The primary outcome measures are: 1) disease-specific
psychopathology: Eating Disorder Examination Ques-
tionnaire (EDE-Q) [70] for AN severity; Yale-Brown Ob-
sessive Compulsive Scale (Y-BOCS) [65, 66] for OCD
severity.
The Eating Disorder Examination Questionnaire
(EDE-Q) [70, 71] is the self-report version of the Eating
Disorder Examination (EDE) [72], a semi-structured
Fig. 1 Study design
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interview to evaluate ED psychopathology. The EDE-Q
assesses attitudinal and behavioural aspects of EDs over
a 28-day period. It has four subscales assessing concerns
about shape, weight and eating, and restraint. The EDE-
Q consists of subscale scores and a total scale score. The
EDE-Q has excellent internal consistency (Cronbach
α 0.78-0.93). The subscales have also excellent test-
retest reliability over a 2-week period (Pearson r ranging
from 0.81 to 0.94) [73].
The 10-item Yale-Brown Obsessive-Compulsive Sever-
ity Scale (Y-BOCS) [74] is a clinician-rated, semi-
structured interview-based scale that is broadly used to
assess obsessive-compulsive symptom severity. The scale
has two parts, each with five questions, with each sub-
scale assessing five aspects of OCD pathology: 1) time
consumed, 2) degree of interference, 3) distress, 4) re-
sistance, and 5) perceived control. The first subscale
gives an obsession score (maximum: 20), the second a
compulsion score (maximum: 20), and together yield a
total score (maximum: 40). It has a strong internal
consistency (Cronbach α .88-.91), inter-rater reliability
(r 0.82–0.98), and test-retest reliability in clinical and
nonclinical samples were excellent.
The secondary outcome measures are: 1) disease-specific
psychopathology: Obsessive-Compulsive Inventory-Revised
(OCI-R) [75], 2) quality of life and daily functioning:
EuroQol (EQ-5D) [76], Eating Disorder Quality of life
questionnaire (ED-QoL) [77], Obsessive Compulsive Dis-
order Quality of life questionnaire (OCD-QoL) [78], and
Work and Social Adjustment Scale (WSAS) [79], 3) cost-
effectiveness (direct and indirect health-related costs as
evaluated by means of patients’ self-reported QoL ratings
and medical and societal burden: Trimbos/iMTA Ques-
tionnaire for Costs associated with Psychiatric illness
(TiC-P) [80], 4) general anxiety: Beck Anxiety Inven-
tory (BAI) [81], and 5) Depression: Beck Depression
Inventory, second revision (BDI-II) [82].
The Obsessive-Compulsive Inventory-revised (OCI-R)
[75] evaluates the frequency, and distress experienced of
OCD symptoms using six subscales: washing, obsessing,
hoarding, ordering, checking, and neutralizing. The
OCI-R has good psychometric properties [75, 83, 84]
and is sensitive to the effects of treatment [85]. Internal
consistency was adequate (obsessing α = .82, washing α
= .86, checking α = .88, neutralizing α = .86, ordering α
= .90, hoarding α = .90, total scale α = .81 ) and test-
retest reliability was excellent (Spearman’s correlations
between .79 and .91) [75].
The EuroQol (EQ-5D) [76] is a standardized self-
report instrument gauging five dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression. Each dimension is rated on three levels (no
problems, some problems, and extreme problems). Fur-
ther, the EQ-5D uses a visual analog scale from 0 to 100,
on which the respondent marks his general well-being.
The EQ-5D is used in a variety of studies to determine
health status in a wide variety of patients.
The Eating disorder Quality-of-Life questionnaire (ED-
QoL) [77] generates a disorder-specific self-rated
quality-of-life score. It consists of 25 items assessing the
influence of eating behaviours/body weight in four sub-
scales: psychological, physical/cognitive, financial, and
work/school. A total score is calculated as the average of
the items of the four subscales. Higher scores indicate a
lower quality of life. The ED-QoL has a good internal
consistency (Cronbach α = 0.84–0.95), and test-retest re-
liability (intraclass correlations were .97 for the psycho-
logical subscale, .87 for the physical/cognitive subscale,
.90 for the financial subscale, .14 for the work/school
subscale, and .93 for the total score) [77].
The Obsessive-Compulsive Disorder Quality of Life
(OCD-QoL) is a self-report questionnaire [78] gauging
the influence of OCD on the respondent’s quality of life.
It was adapted from the ED-QOL and thus also has four
subscales: psychological, physical/cognitive, financial and
work/school, whose 25 items are scored and interpreted
similarly.
The Work and Social Adjustment Scale (WSAS) [79]
examines to which extent the disorder has caused the
patient functional impairment. A total score of 10 or
below is normal, with scores of 10–20 indicating signifi-
cant functional impairment but less severe clinical symp-
tomatology, and scores of 20 and above suggest
moderate to severe impairment or more severe psycho-
pathology. The test-retest correlation for the total WSAS
score was 0.73 and the scale has an acceptable to good
internal consistency (Cronbach alpha 0.79–0.88).
The Trimbos/iMTA questionnaire for costs associ-
ated with psychiatric illness (TIC-P) [80] evaluates the
utilization of medical services such as the number of
contacts with the general practitioner and other care
providers (e.g., medical specialists and paramedics) as
well as medication used during the last 3 months.
The costs associated with the experimental and con-
trol interventions delivered during this study will be
calculated as recommended in the Dutch handbook
on cost calculations in health care [86]. Reference
unit prices of corresponding health-care services will
be used and cost-utility calculated by relating the dif-
ference in direct medical costs per patient receiving
CRT + TAU and SAT + TAU to the difference in terms
of quality-adjusted life years (QALY) gained (cost-util-
ity), yielding a QALY estimate.
The Beck Depression Inventory, second revision (BDI-
II) [82] is a gold-standard self-report measure to assess
the severity of depressive symptoms. The BDI-II com-
prises 21 categories of statements. Respondents are
asked to choose the statement that describes the way
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they felt in the past 2 weeks. Each item is rated on a 4-
point Likert-type scale ranging from 0 to 3, with higher
scores indicating higher levels of depression. The max-
imum total score for all 21 items is 63. Score categories
range from 0 to 13 (minimal depression), 14 to 19 (mild
depression), 20 to 28 (moderate depression), and 29 to
63 (severe depression). The BDI-II has good psychomet-
ric properties [87]. The BDI-II shows good validity com-
pared to the Hamilton Depression Rating Scale
(Pearson’s r of 0.71). The inventory has high internal
consistency (Cronbach α = .91) [88].
The Beck Anxiety inventory (BAI) [81] gauges symp-
toms of anxiety (such as trembling hands, dizziness,
sweating) by means of 21 questions. Respondents indi-
cate if and to what extent they have experienced any
symptoms during the past week on a 4-point Likert scale
ranging from 0 (not at all) to 3 (severely). The BAI dis-
criminates well between anxious and non-anxious
groups and is useful as screening measure for anxiety in
a variety of clinical populations. The BAI has a high val-
idity and high internal consistency (α .92).
Mediators
The following variables will be tested as potential media-
tors of intervention response: 1) cognitive flexibility,
using a Stroop task [89], including Delis-Kaplan Execu-
tive Function System (D-KEFS) card nr. 4, as well as
Detail and Flexibility Questionnaire (D-Flex) [90], Trail
Making Test (TMT) [91], 2) response inhibition: Stop
Signal Reaction Task (SSRT) [92], 3) Central coherence:
Group embedded figures test (GEFT) [93], 4) Intoler-
ance of uncertainty: Intolerance of Uncertainty Scale
(IUS) [94], 5) Perfectionism: Clinical Perfectionism
Questionnaire (CPQ) [95], 6) Self-efficacy: Perceived
Efficacy in Patient-Physician Interactions (PEPPI-5) [96],
7) Behavioural Inhibition and Behavioural Activation
Scales (BISBAS) [97], and 8) therapeutic engagement
Session Rating Scale (SRS) [98].
The Stroop-task was originally developed by Stroop
[89] to easily measure selective attention and cognitive
flexibility. The Stroop Color-Word Test has three com-
ponents. Patients are first asked to name a series of col-
ored words to reflect basic reading rate. They are next
asked to name the color (red, blue, or green) of a bar.
The final component comprises a Color-Word task in
which the participant is shown the names of colors
printed in conflicting ink colors (e.g., the word “green”
in blue ink) and is asked to name the color of the ink ra-
ther than the word. For all tasks, patients are timed by
the tester to determine the number of seconds needed
to identify all the stimuli, and, for the interference con-
dition, the number of uncorrected errors is recorded.
The ‘Stroop Effect’ is calculated by subtracting the differ-
ence between the interference and color patch task
times, where lower scores indicate better executive func-
tioning. Average test-retest reliability for the Stroop task
is high (r = 0.84) [99]. In the present study we use the
Color-Word interference test from the D-KEFS test-
battery [100].
The D-Flex [90] is a 24-item self-report scale that
measures cognitive rigidity (difficulty with set-shifting/
flexibility) and attention to detail (weak central coher-
ence). The two subscales showed high internal
consistency (Cronbach α 0.90–0.95), construct validity
(as compared to relevant subscales of the AQ) was
strong for cognitive rigidity (r = 0.72) but moderate for
attention to detail (r = 0.26).
The Trail Making Test (TMT) [91] is used to evaluate
set-shifting abilities. Originally a pen-and-paper test,
more recently a computerized version has become avail-
able. Patients numerically or alphabetically connect cir-
cles on a page in a ‘ dot-to-dot ’ fashion (trail A), and
then alternatively link numbers and letters, i.e. 1–A–2–
B–3–C (trail B). Time taken to complete trail B (switch-
ing task) is the outcome measure of set-shifting ability.
When performing the computerized Stop Signal Task
(SSRT) [92] patients need to rapidly select correspond-
ing motor responses to left- or right-facing arrows
appearing on a computer screen and attempt to inhibit
responses when an auditory “stop signal” sounds. Using
a tracking algorithm, the task estimates the time taken
to internally suppress prepotent motor responses (stop-
signal reaction times).
The Group Embedded Figures Test (GEFT) [101] is a
paper-and-pencil task commonly used as a measure of
central coherence. The time taken to find 18 simple
shapes embedded in complex designs is recorded, with
the main outcome being the total time needed to locate
all hidden shapes, where shorter times are assumed to
result from a strong local processing capacity or a bias
toward detail.
The Intolerance of Uncertainty Scale (IUS) [94, 102,
103] was developed to assess reactions to ambiguous sit-
uations, uncertainty, and future events. The IUS has
been investigated and validated in various populations to
measure intolerance of uncertainty. The IUS includes 27
items relating to the idea that uncertainty is unaccept-
able, reflects badly on a person, and leads to frustration,
stress, and the inability to take action. Respondents rate
items on a 5-point Likert scale ranging from 1 = “not at
all characteristic of me” to 5 = “entirely characteristic of
me”. The Dutch version has high internal consistency
for anxiety-disordered patients (Cronbach α = 0.94) and
a satisfactory test-retest reliability (r = 0.79).
The Clinical Perfectionism Questionnaire (CPQ) as-
sesses degrees of perfectionism. Respondents are pre-
sented with 12 items describing different expressions of
perfectionism and asked to rate these on a 4-point Likert
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scale in relation to the last 28 days. Total score is the
sum of all scores and range from 12 to 48, with higher
scores indicating higher clinical perfectionism. There is
evidence showing the CPQ to be a promising and
reliable measure of clinical perfectionism. It has an ac-
ceptable internal consistency (Cronbach α = 0, 71) and
test-retest reliability (r = 0.49–0.67) [95, 104].
With the Perceived Efficacy in Patient-Physician Inter-
actions (PEPPI-5) [96] patients rate their sense of confi-
dence or self-efficacy in regard to their interactions with
their physician on a 5-point Likert scale ranging from
‘not at all confident’ (1) to ‘very confident’ (5). The in-
strument has been translated and validated for use in
the Netherlands [105]. The range of possible scores is 5
to 25, with 25 reflecting highest-level self-efficacy. The
PEPPI-5 has a high internal consistency (Cronbach alpha
0.92) and a fair test-retest reliability (intra-class correl-
ation coefficient 0.68).
The Behavioural Inhibition and Behavioural Activation
Scale (BISBAS) [97] is a 20-item instrument designed to
measure behavioural inhibition (i.e., concern over and
reactivity to aversive events) and behavioural activation
(i.e., responsiveness to incentives, drive, and fun seek-
ing). Patients respond to the items using a 4-point scale,
ranging from 1 (quite untrue) to 4 (quite true). After re-
verse scoring of two items on the BIS, subscale scores
are computed by summing the scores corresponding to
items on the BIS scale (7 items, range 7–28, α .74). The
BAS-scale (13 items, range scores 13–52) consists of the
reward responsiveness scale (5 items, α .73), the drive
scale (4 items, α .76), and the Fun Seeking scale (4 items,
α .66). Test-retest correlations over an 8 week period are
satisfactory (r from 0.59 to 0.69). The BIS correlates
moderately highly with measures of trait anxiety, nega-
tive affect, and negative temperament. The BAS corre-
lates positively with extraversion, positive affect, and
positive temperament.
The Session Rating Scale (SRS) [98] is a short, 4-item,
self-report questionnaire probing therapeutic alliance.
After each session patients are asked to give their impres-
sions of the preceding session using a VAS. They rate their
bond with the therapist, agreement on therapy goals and
therapy tasks, and their confidence in the collaboration,
where ratings can range from “there was something miss-
ing in the session today” to “Overall, today’s session was
right for me”. The Dutch translation of the SRS has been
shown to have a strong internal consistency (Cronbach
alpha 0.85–0.95) and adequate test-retest reliability [106],
although in the Dutch study correlations with outcome
and concurrent validity were lower than expected.
Moderators
The following variables will be tested as potential mod-
erators of intervention response: 1) demographic
variables (e.g. sex, age, educational level), 2) general psy-
chopathology: Structured Clinical Interview for DSM-
IV-TR Axis I disorders (SCID-I) [64], Structured Clinical
Interview for DSM-IV-TR Axis II disorders, section
obsessive-compulsive personality disorders (SCID-II-
OCPD) [68], 3) Autism: Autism-spectrum Quotient
(AQ) [107], 4) Attention-deficit hyperactivity disorder:
Connors’ adult ADHD Rating Scales CAARS-S:SV)
[108], 5) Cognitive flexibility: Intra dimensional-/extra
dimensional shift paradigm (ID/EDS) [109], and 6) Plan-
ning ability: Behavioural Assessment of the Dysexecutive
Syndrome, Zoo MAP (BADS-Zoo map) [110]. The SSRT,
IUS, and BADS-Zoo map will be taken for OCD only.
The autism-spectrum quotient (AQ) [107] is a self-
report questionnaire that assesses traits associated with
the autistic spectrum [111]. It consists of five 10-item
subscales (social skills, attention switching, communica-
tion, imagination, attention to detail). Example items of
the AQ are: “I find myself drawn more strongly to
people than to things” and “Trying to imagine some-
thing, I find it easy to create a picture in my mind”. Re-
spondent rate each item on a 4-point Likert scale from
“definitely agree” to “definitely disagree”. A score of ≥ 32
is indicative of an autism spectrum disorder. The index’s
test-retest reliability is good (r = .60 to .81) and internal
consistency is acceptable (α = .71) [112].
The Connors’ Adult ADHD Rating Scales self-report,
short version (CAARS-S:SV) [108] comprises 30 items
on the presence of ADHD symptoms to be rated on a 4-
point Likert scale ranging from 0 (not at all), to 3 (very
much). The maximum score for al 30 items is 90. The
CAARS-S:SV consists of 5 subscales (inattention/memory
problems, hyperactivity/restlessness, impulsivity/emo-
tional lability, problems with self-concept, and ADHD-
index). The internal consistency is good, ranging from
α = .80 to .89 and it has an acceptable test-retest reli-
ability (r = 0.58 to 0.77).
The Intra-dimensional/extra-dimensional shift task
(ID/EDS) [109] is part of the Cambridge Neuropsycho-
logical Test Automated Battery (CANTAB). The version
used in the current trial is a replication of the original
task. The ID/EDS is a reliable and valid computerized
task, which, like the TMT, probes set-shifting ability
[113–115]. The paradigm involves nine-stages of a visual
discrimination task with multidimensional stimuli. Two
stimuli are displayed, and feedback is provided which
stimulus is correct. To pass to the next stage, six con-
secutive correct responses are required within 50 trials;
if not, the task ends. The rule for correct responding is
modified at the start of each task stage.
The Zoo Map is part of the Behavioural Assessment of
the Dysexecutive Syndrome test battery (BADS) [110]
and consists of two parts. In the first part, patients are
instructed to plan their route through a map of a zoo,
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visiting a selection of locations while actively disregard-
ing others. While planning the route, patients also
instructed to obey certain rules. The second part con-
sists of the same map with the same locations that have
to be visited, but this time, instructions are provided
about the precise order in which the locations must be
visited. Therefore, in contrast to the first part, the sec-
ond part consists of a highly structured setting that
strongly reduces the involvement of planning abilities.
The BADS-Zoo map subtest has been proven to be a
valid indicator of planning ability in a heterogeneous pa-
tient sample [116].
Power and sample-size calculation
In accordance with Cohen [117], we calculated the sam-
ple sizes needed to detect treatment-specific differences:
CRT + TAU vs. SAT + TAU, for which we used software
by G-power [118].
We based effect-size calculations on Dingemans’ first
RCT [57] comparing CRT + TAU with TAU alone for
eating disorders in which they obtained large effect sizes
for reduction in eating disorder pathology (Cohen’s d:
0.99). Given the control condition in this study we take
into account a smaller effect-size. In the case of two-
tailed MANOVAs, repeated measures and four within-
between interactions (2 groups: AN and OCD), two
conditions (CRT + TAU vs. SAT + TAU), three measure-
ments (baseline, and 2, and 6 months after baseline),
with alpha = 0.05, a sample size of 113 patients is needed
to have a power of at least 0.80 to detect an effect size
f(V) of 0.25. Although the dropout rate in the previous
CRT studies of Dingemans was low (n = 7 out of 82
patients), we have opted to include an additional 15 pa-
tients to compensate for attrition, totalling 128 patients
in total (64 CRT + TAU and 64 SAT + TAU).
Interventions
CRT and SAT are both delivered in 10 bi-weekly sessions
directly preceding TAU. As AN patients will need to be
closely monitored and given nutritional advice through-
out the study, the relevant treatment components will
be part of the first treatment phase in this group. Other
components of (psychological) treatment will not be of-
fered until CRT/SAT has been completed.
Cognitive remediation therapy
In this trial, CRT is based on the Dutch translation of
the original manual by Kate Tchanturia [119] for both
patient groups. Comprising 10 twice weekly 45-min ses-
sions, CRT is delivered by psychologists, clinical nurses,
and psychology students (at the MSc level), all having
been trained by experienced CRT therapists (UD, BvP,
LS, DC) who themselves were trained by Dr Kate
Tchanturia, expert on CRT for eating and weight
disorders. Using a range of cognitive lab-based exercises,
CRT aims at improving patients’ set-shifting, cognitive
flexibility, global information processing skills, and at re-
ducing perfectionism. Table 2 lists the within-session ex-
ercises used in the RCT.
For a more detailed description of the exercises, see
Tchanturia et al. [119]. With respect to carrying out the
exercises, awareness of dysfunctional thinking styles is
enhanced. Patients are encouraged to find out how these
thinking styles affect their daily lives, and from session 2
onward, homework assignments are given comprising
behavioural exercises that are closely linked to real-life
skills and tasks to thus stimulate patients to practice
more flexible behaviours in their everyday lives.
Specialized Attention Therapy (SAT)
SAT has been designed as the control intervention spe-
cifically for this trial. SAT is delivered by the same health
professionals delivering CRT. The SAT session structure
(10 twice weekly, 45-min sessions and homework assign-
ment) is the same as in CRT. However, during SAT, cog-
nitive flexibility, central coherence, global information
processing skills, awareness of thinking styles, and redu-
cing perfectionism are not addressed. Instead, after each
task patients are asked their opinion on whether they
(dis)liked the task. As a treatment rationale, patients are
explained that SAT aims at helping them to focus on
positive experiences by means of tasks and exercises,
where each session–again in line with CRT–comprises
different exercises. For an overview of the exercises
practiced in SAT, see Table 3; for a more detailed de-
scription of the exercises, the SAT treatment manual is
available upon request [120].
From session 2 onward, patients are encouraged to en-
gage in similar activities at home that they enjoy.
Treatment as usual
After completion of either CRT or SAT, patients receive
TAU. The content of TAU comprises all the essential
Table 2 CRT exercises
Central coherence tasks Maps
Summarize a letter
Hidden words
Word-search task
Embedded word task
Set shifting tasks Card Stack
Visual illusions
Stroop material
Switching attention task
Switching Time Zones
Alphabet task
Perfectionism tasks Estimation task
Strategy tasks How to plant a sunflower
Complex figure task
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elements recommended in the Dutch guidelines on eat-
ing disorders and OCD, which are closely related to the
international guidelines [121, 122].
TAU for patients with AN consists of normalization of
eating behaviours (weight gain), discussion of daily prob-
lems, goals, psycho-education, and for a subgroup psy-
chomotor therapy, art therapy, social skills training,
family-therapy or cognitive behavioural therapy. Psychi-
atric- and/or medical consultation and pharmacotherapy
is given where needed.
TAU for OCD patients comprises CBT delivered in 20
to 30 weekly or twice weekly 45–90 min sessions in
which exposure with response prevention forms a key
element, consistent with the multidisciplinary guidelines
for anxiety disorders (OCD chapter) [121]. In line with
the literature [123, 124], the OCD protocol is flexible,
i.e., patient-tailored with regard to the time spent on
each component, accounting for differences in session
and treatment duration. The therapy encompasses a)
psychoeducation, b) cognitive therapy, c) exposure in
vivo with response prevention, d) psychiatric consult-
ation, and, in case of severe symptoms, pharmacotherapy
with SSRIs, venlafaxine, clomipramine and/or atypical
antipsychotics. The protocol allows for one or two ses-
sions in which the principles of CBT are explained and
one or two sessions in which an inventory is made of all
anxiety/tension-provoking situations that give rise to
compulsions and a construction of a list of compulsion
triggers. All patients receive in- and between session ex-
posure to anxiety-provoking thoughts and situations,
coupled with prolonged response prevention tailored to
their individual symptoms.
Treatment fidelity
To ensure treatment fidelity for CRT and SAT, the best
practices and recommendations from the NIH Behaviour
Change Consortium [125] are followed. The number,
duration, and frequency of sessions, as well as patient-
therapist contact times are kept the same for CRT and
SAT. All patient-therapist contacts are formally sched-
uled to ensure fixed durations. All treatment sessions
are audio- or videotaped and an external checker not in-
volved in the trial rates treatment fidelity in a random
selection of 10% of the recorded sessions. To evaluate,
guide, and approve interventions, and to constrain ‘ther-
apist drift’, all therapists are supervised by expert profes-
sionals, and have at least monthly intervision-sessions.
After every session, the therapist completes a brief ques-
tionnaire to record treatment stage and components de-
livered. Deviations from the protocol are reported to the
supervisor.
Analyses
Baseline differences between the CRT and SAT (control)
groups and between the participating centres are investi-
gated using χ2 tests for categorical variables and
ANOVAs for continuous variables. Additional explora-
tory analyses are conducted separately for AN and OCD.
The data for the primary AN and OCD outcome indi-
ces are analysed using linear mixed models (LMM) with
the baseline value as a covariate. The mixed models ana-
lysing the general efficacy of CRT include a random
term for the intercept and fixed terms for condition,
time contrasts (T0–T1, T0–T2, T0–T3, T1–T2, T1–T3),
and the interactions between condition and time
contrasts.
In order to investigate moderators of short- and long-
term treatment response, time contrasts are created
(T0–T1, T0–T2, T0–T3, T1–T2, T1–T3) by means of
dummy coding. Potential continuous moderator vari-
ables are standardized. Interactions between condition
and the potential moderators are entered into the equa-
tion. All analyses on therapy effect modificators are of
an exploratory nature. The moderator and mediator ana-
lyses are calculated with 5000 bootstraps [126].
To assess the cost-effectiveness of CRT + TAU versus
SAT + TAU for ED and OCD, all relevant costs and ef-
fects are taken into account. Disease progression is de-
scribed in terms of transitions between ‘states’, where a
patient’s ‘state’ can shift in either direction or remain
constant. Estimations of state-transition rates are based
on the data from the ongoing trial and the literature,
which modelling approach serves to help us assess fu-
ture scenarios. Costs and effects are calculated in ac-
cordance with recommendations in the Dutch guideline
for economic evaluation of health care. As a primary as-
sessment we apply a costs-utility analysis that yields a
cost per quality-adjusted life years (QALY) outcome, a
common cost-effectiveness measure that allows com-
parison with economic evaluations of other diseases and
interventions. The uncertainty estimations are computed
Table 3 SAT exercises
Motor tasks Djenga
Mikado
Leaning Tower of Pisa
Operation Game
Luck tasks Game of the Goose
Ludo
Snakes and ladders
Collaboration task Drawing a picture together
Picture tasks Spot the differences
Viewing a picture
Verbal tasks Last letter-first letter
Incomplete sentences task
Poems
Additional tasks Listening to music
Analogies
Categories
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using bootstrapping and the results expressed in an ac-
ceptability curve. If no intervention is effective, a cost-
minimization calculation is performed.
Discussion
Inefficiencies in cognitive flexibility and central coher-
ence are problematic in psychiatric disorders. CRT aims
at addressing these inefficiencies and thus enhancing
treatment outcome. To our knowledge, this is the first
randomized controlled trial using a control condition
evaluating the efficacy and effectiveness of CRT as a
treatment enhancer preceding TAU for AN, and the first
study to investigate CRT in OCD, moreover taking cost-
effectiveness of CRT in AN and OCD into account. This
study enables us to establish whether the anticipated
treatment-enhancing effect of CRT is achieved by im-
provement of the patients’ cognitive flexibility. With this
transdiagnostic approach, we will additionally learn
whether CRT challenges a diagnosis-specific problem or
taps shared underlying mechanisms for AN and OCD.
Another strength of our trial is that CRT effectiveness
is investigated in established clinics specialized in the
treatment of patients with severe symptoms.
A potential limitation of this trial is the fact that we
have not tested the validity of SAT as a control condi-
tion, i.e. a condition that lacks the potential working
mechanisms of CRT . Further, the credibility of SAT as
an alternative treatment to CRT has not been tested.
After baseline assessment, patients are told which inter-
vention they receive (CRT or SAT). Although they are
not told that CRT is the therapy-enhancer being investi-
gated and that SAT is offered as a control intervention,
patients might be able to ‘guess’ which therapy entails
the control condition, potentially biasing treatment ex-
pectancy and credibility.
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